fda warning letter bpc 157 peptide unapproved drug bpc-157 new BPC-157: Miracle Healing or Hidden Danger? FDA Targets GLP-1 and Peptide

Kashyap S, Gowda P, Pasanna RM, et al

These include: Mild nausea or digestive discomfort (more common with oral forms) Dizziness or lightheadedness Injection site irritation, redness, or swelling Possible changes in appetite These side effects typically go away on their own and do not pose long-term risks

For a once-weekly injection, that equates to approximately 12 to 13 doses

In general, there is the cytoprotection concept: the described effects of the stable gastric pentadecapeptide BPC 157 (that has been found to be safe in ulcerative colitis trials, phase II, without a lethal dose (LD1) in the toxicology studies) were ascribed to its particular cytoprotective capabilities and pleiotropic background as an acting cytoprotective peptide that protects cells and may cure muscle disturbances in particular [11,12,13,14,24,25]